Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Inclusion Criteria: * Patients must have histologically confirmed relapsed/refractory or previously untreated mantle cell lymphoma (any stage) * Patients with untreated MCL should be asymptomatic or minimally symptomatic from their MCL and without aggressive clinicopathological features that would otherwise warrant immediate intensive therapy; these will generally be patients who qualify for an initial period of "watch and wait" per clinical discretion * Patients must have metabolically active (positron emission tomography \[PET\] scan positive) measurable disease (defined as lesions greater than 1.5 cm long axis that can be accurately measured in two dimensions by computed tomography \[CT\]) * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Absolute neutrophil count (ANC) \>= 1000/mm\^3 or \>= 750/mm\^3 in the setting of marrow involvement by disease (independent of growth factor or transfusion support) * Platelets \>= 50,000/mm\^3 or \>= 30,000/mm\^3 in the setting of marrow involvement by disease or splenomegaly due to disease (independent of growth factor or transfusion support) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x upper limit of normal (ULN) * Total bilirubin =\< 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin * Creatinine clearance (CrCl) \>= 30 mL/min (as calculated by Cockcroft-Gault equation) * All patients must be informed of the investigationa…